The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Shares of Vertex Pharmaceuticals plunged more than 14% to $404.89 after it release disappointing top-line results from its recently completed Phase II, randomized, double-blind, placebo-controlled ...